B. Riley analyst Mayank Mamtani raised the firm’s price target on CymaBay Therapeutics to $22 from $16 and keeps a Buy rating on the shares. The company reported strong top-line pivotal Phase III RESPONSE study results of seladelpar in primary biliary cholangitis, the analyst tells investors in a research note. The firm says the data hit the “bull case.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CBAY:
- CymaBay (NASDAQ:CBAY) Rises on Promising Phase 3 Results in Liver Disease
- CymaBay price target raised to $33 from $17 at Raymond James
- CymaBay RESPONSE data ‘positive all-around,’ says H.C. Wainwright
- CymaBay announces Phase 3 RESPONSE study achieved primary endpoint
- CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023